Vertex Pharmaceuticals Logo

Email this page: News Release

Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People With the Most Common Form of the Disease

For security reasons, registration is required before you can use this feature.
* Indicates required field